2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-U00254
    L791943 192767-01-4
    L791943 is a potent, selective Phosphodiesterase-4 (PDE4) inhibitor with an IC50 of 4.2 nM.
    L791943
  • HY-U00271
    Pareptide monohydrochloride 63236-23-7
    Pareptide monohydrochloride is a melanotropin-inhibiting factor (MIF) metabolically stable analogue.
    Pareptide monohydrochloride
  • HY-U00280
    Potassium Channel Activator 1 908608-06-0 98.43%
    Potassium Channel Activator 1 is an agent for treating, one or more disorders or conditions wherein the dopaminergic system is disrupted, such as one or more disorders or conditions independently selected from the group consisting of: schizophrenia and other psychotic states; mood disorders ADHD; aggression; movement disorders.
    Potassium Channel Activator 1
  • HY-U00287
    BACE-IN-1 1254166-60-3
    BACE-IN-1 (Compound 13) is a substituted lmidazo[1 ,2-a]pyridine derivative which can inhibit β-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment of diseases in which BACE is involved, such as Alzheimer's disease.
    BACE-IN-1
  • HY-U00310
    Neuromuscular-targeting compound 1 1178978-20-5
    Neuromuscular-targeting compound 1, extracted from patent WO2009099594 A1, Paragraph 0100, is useful in treatment of neuromuscular diseases.
    Neuromuscular-targeting compound 1
  • HY-U00314
    Anti-neurodegeneration agent 1 289893-23-8
    Anti-neurodegeneration agent 1 a neurodegeneration-targeting compound extracted from patent WO2008039514A1, Compound I.
    Anti-neurodegeneration agent 1
  • HY-U00316
    Vinconate 70704-03-9
    Vinconate is an indolonaphthyridine derivative and can stimulate the muscariic acetylcholine receptor.
    Vinconate
  • HY-U00333
    α1 adrenoceptor-MO-1 161905-64-2
    α1 adrenoceptor-MO-1, an S enantiomer, has affinity at alpha 1 adrenergic receptor, shows alphalytic activity, and possesses analgesic action; more active than R enantiomer.
    α1 adrenoceptor-MO-1
  • HY-U00338
    Verilopam 68318-20-7
    Verilopam is a potent analgesic.
    Verilopam
  • HY-U00343
    MAO-B-IN-1 1124198-17-9
    MAO-B-IN-1 is an inhibitor of monoamine oxidase B, used for the research of neurological diseases.
    MAO-B-IN-1
  • HY-U00348
    Anticonvulsant agent 1 357336-17-5
    Anticonvulsant agent 1 is an anticonvulsant agent extracted from patent WO2001062726A2, Compound 156.
    Anticonvulsant agent 1
  • HY-U00357
    Urinary Incontinence-Targeting Compound 1 137315-05-0
    Urinary Incontinence-Targeting Compound 1 is a sulfonanilide derivative, used in the research of urinary incontinence.
    Urinary Incontinence-Targeting Compound 1
  • HY-U00362
    Neurodegenerative Disorder-Targeting Compound 1 1254698-39-9
    Neurodegenerative Disorder-Targeting Compound 1 is a calpain inhibitor extracted from patent WO2010128102A1, compound example 63.
    Neurodegenerative Disorder-Targeting Compound 1
  • HY-U00368
    5-HT3 antagonist 1 129294-09-3
    5-HT3 antagonist 1 is a potent and selective antagonist of serotonin 3 (5-HT3) receptor.
    5-HT3 antagonist 1
  • HY-U00371
    AR-08 226081-74-9
    AR-​08 is an agonist of α2-adrenergic receptor, used for the treatment of attention deficit hyperactivety disorder (ADHD).
    AR-08
  • HY-U00372
    2: PN: US20040072744 SEQID: 2 claimed protein 389572-87-6
    2: PN: US20040072744 SEQID: 2 claimed protein is a synthetic peptide, used for the research of Down's syndrome and schizophrenia.
    2: PN: US20040072744 SEQID: 2 claimed protein
  • HY-U00374
    Sch59498 224157-99-7
    Sch59498 is a potent inhibitor of phosphodiesterase 1c (Pde1c).
    Sch59498
  • HY-U00385
    Neuromuscular Disorder-Targeting Compound 1 374538-23-5
    Neuromuscular Disorder-Targeting Compound 1 is used in the research of neuromuscular disorders such as symptoms of fibromyalgia syndrome and chronic fatigue syndrome.
    Neuromuscular Disorder-Targeting Compound 1
  • HY-U00388
    α2δ ligand 1 313653-15-5
    α2δ ligand 1 is a ligand to the α2δ-1 subunit of voltage-sensitive calcium channel, extracted from patent US20040186177.
    α2δ ligand 1
  • HY-U00392
    Tachykinin angatonist 1 178310-77-5
    Tachykinin angatonist 1 is a neurokinin receptor antagonist extracted from patent US5968923, compound example 32.
    Tachykinin angatonist 1
Cat. No. Product Name / Synonyms Application Reactivity